Pharmaceuticals & Therapeutics

Navigator Medicines pushes two novel bispecific antibodies for Hidradenitis Suppurativa, promising better efficacy and patient-friendly dosing.

New 3-year trial data shows UCB's BIMZELX prevents painful flares in most HS patients, highlighting a critical window for early intervention.

Dr. Murad Alam begins his presidency of the American Academy of Dermatology, bringing deep policy and research expertise to lead the field's challenges.

FDA greenlights a novel, AI-discovered therapy for a Phase 1 trial, offering new hope for children with devastating central nervous system tumors.

With a $150M war chest, OnKure pivots to a new class of PI3Kα inhibitors, aiming to revolutionize treatment for breast cancer and rare diseases.

With a fresh Nasdaq listing and $57.2M in funding, Satellos is advancing a novel muscle-regenerating drug for Duchenne into pivotal pediatric trials.

Biocon names 30-year veteran Shreehas Tambe as its new CEO, consolidating its biosimilar and generics arms to create a global biopharma powerhouse.

Neapco's acquisition of IFA Group is complete, creating a global automotive driveline leader with nearly $2B in sales and a vast, integrated portfolio.

INNOVATE Corp. reports a 62% Q4 revenue surge, but a 'going concern' warning and looming debt have forced the company to explore selling key assets.

At a key investor conference, Renibus is pitching its two Phase 3 drugs, including one with a strategic pivot after a challenging trial result.

As GLP-1 drug demand soars, Nordic Cold Chain Solutions launches a new lab to solve the complex puzzle of keeping these sensitive medicines safe.

A new report slams the FDA for blocking vital treatments with rising costs and denials, but the agency faces a complex reality of reform and internal pressure.

The nation's top aesthetic clinic partners with BENEV to exclusively debut XTherma®, the first RF and cryogen device for pain-free skin rejuvenation.

A novel three-in-one antibody from CStone shows a 90% response rate in lung cancer and potent activity in 'cold tumors,' heralding a new era for immunotherapy.

Healthcare powerhouse Terri Cooper joins Morphic Medical's board, a strategic move to navigate clinical trials for its non-surgical RESET diabetes therapy.

A new lithium formula boosts brain delivery in a key trial, offering hope for safer, more effective treatments for Alzheimer's, bipolar disorder, and more.

The Arabic beauty brand unveiled its new serum-infused foundation and primer at Cosmoprof Bologna, tapping into the growing demand for experience-led beauty.

The successful launch of rosacea treatment Emrosi™ generated $14.7M, driving Journey Medical's revenue to $61.9M and signaling a major strategic win.

Investview rebrands its controversial iGenius platform to Conectiv, adding wellness. But can a new name escape a history of regulatory fines and pyramid scheme allegations?

A potential first-ever treatment for a severe rare skin disease gets a major boost from the FDA, accelerating its path to patients and exciting investors.